Sign in
4

Changes in Ownership

Rapport Therapeutics, Inc. Filed Acc 0000950170-25-087897

Chief Scientific Officer sold 8,500 shares at $11.00 ($93,522)

  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Bredt David Chief Scientific Officer 2025-06-16 Sale 10b5-1 −8,500 $11.00 $93,522 443,642 D
Open-market sales · 8,500 sh · avg $11.00 · $93,522
Loading xslF345X05/ownership.xml…